Cardiovascular–kidney–metabolic syndrome: novel molecular mechanism and glucagon-like peptide-1-targeting therapy
- 1Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China
- 2Ningbo Municipal Hospital of Traditional Chinese Medicine, Affiliated Hospital of Zhejiang Chinese Medical University, Ningbo, China
Abstract
Cardiovascular–kidney–metabolic (CKM) syndrome represents a systemic disease continuum arising from the progressive and reciprocal interactions among metabolic dysfunction, kidney injury, and cardiovascular disease. Obesity and type 2 diabetes mellitus (T2DM) are major metabolic drivers of early CKM progression and contribute to cardiac and kidney injury through insulin resistance, glucotoxicity and lipotoxicity, chronic inflammation, oxidative stress, mitochondrial dysfunction, and ectopic lipid deposition, thereby establishing a self-reinforcing vicious cycle across the metabolic, cardiovascular, and renal systems. Glucagon-like peptide-1 (GLP-1) and its receptor (GLP-1R) not only participate in the regulation of glucose homeostasis and energy metabolism but also represent an important regulatory nexus linking metabolic dysfunction to cardiorenal injury. GLP-1 receptor agonists (GLP-1RAs) improve metabolic homeostasis by enhancing glucose-dependent insulin secretion, suppressing glucagon release, reducing appetite and body weight, and decreasing visceral and ectopic fat accumulation. In parallel, they may exert renal and cardiovascular protective effects by improving endothelial function and microcirculation, suppressing inflammation and oxidative stress, maintaining mitochondrial homeostasis, and attenuating fibrosis. In recent years, large-scale clinical studies have further extended the benefits of GLP-1RAs beyond glycaemic control and weight reduction to improved kidney outcomes, reduced major cardiovascular events, and benefits in obesity-related heart failure with preserved ejection fraction. Meanwhile, natural products, characterised by multi-component, multi-target, and multi-pathway actions, may provide a complementary strategy for integrated CKM management by simultaneously improving glucose and lipid metabolic disturbances, insulin resistance, inflammation, and oxidative stress, while attenuating cardiac remodelling, kidney injury, and fibrosis. Emerging studies have shown that some natural products can concurrently improve metabolic, cardiac, and renal phenotypes in CKM-related diseases or composite disease models. This review focuses on the interactions among the metabolic, renal, and cardiovascular systems in CKM, summarises the biological basis and signalling mechanisms of the GLP-1/GLP-1R system, and highlights the mechanistic and clinical evidence supporting GLP-1RA-mediated protection against obesity- and T2DM-related metabolic dysfunction and cardiorenal injury. The potential value of natural products in comprehensive CKM intervention and future research directions are also discussed.
Related
- Mechanism-based therapeutic strategies in cardiovascular-kidney-metabolic syndrome: integrating biological pathways with evidence from clinical trials
- Depression, functional disability, and cardiovascular disease in adults with cardiovascular-kidney-metabolic syndrome stages 0–3: a nationally representative cohort study
- Association of sleep time with all-cause and cardiovascular mortality among individuals with advanced cardiovascular-kidney-metabolic syndrome : A NHANES-based prospective cohort study
- Machine learning based predictive model for cardiovascular disease mortality risk in patients with stage 4 cardiovascular–kidney–metabolic syndrome
- Heavy metal exposure and risk of all-cause and cardiovascular mortality in population with cardiovascular-kidney-metabolic syndrome stage 0–3: a cohort study
BibTeX
@article{liu2026cardiovascularkidneymetabolic,
title = {{Cardiovascular–kidney–metabolic syndrome: novel molecular mechanism and glucagon-like peptide-1-targeting therapy}},
author = {Fengzhao Liu and Zihan Xu and Wenru Wang and Junwei Gao and Changgeng Fu and Peng Liu},
journal = {Frontiers in Cell and Developmental Biology},
year = {2026},
month = oct,
doi = {10.3389/fcell.2026.1996288},
url = {https://doi.org/10.3389/fcell.2026.1996288},
note = {CC BY},
}
RIS
TY - JOUR
TI - Cardiovascular–kidney–metabolic syndrome: novel molecular mechanism and glucagon-like peptide-1-targeting therapy
AU - Fengzhao Liu
AU - Zihan Xu
AU - Wenru Wang
AU - Junwei Gao
AU - Changgeng Fu
AU - Peng Liu
PY - 2026
DA - 2026/10/23
JO - Frontiers in Cell and Developmental Biology
DO - 10.3389/fcell.2026.1996288
UR - https://doi.org/10.3389/fcell.2026.1996288
AB - Cardiovascular–kidney–metabolic (CKM) syndrome represents a systemic disease continuum arising from the progressive and reciprocal interactions among metabolic dysfunction, kidney injury, and cardiovascular disease. Obesity and type 2 diabetes mellitus (T2DM) are major metabolic drivers of early CKM progression and contribute to cardiac and kidney injury through insulin resistance, glucotoxicity and lipotoxicity, chronic inflammation, oxidative stress, mitochondrial dysfunction, and ectopic lipid deposition, thereby establishing a self-reinforcing vicious cycle across the metabolic, cardiovascular, and renal systems. Glucagon-like peptide-1 (GLP-1) and its receptor (GLP-1R) not only participate in the regulation of glucose homeostasis and energy metabolism but also represent an important regulatory nexus linking metabolic dysfunction to cardiorenal injury. GLP-1 receptor agonists (GLP-1RAs) improve metabolic homeostasis by enhancing glucose-dependent insulin secretion, suppressing glucagon release, reducing appetite and body weight, and decreasing visceral and ectopic fat accumulation. In parallel, they may exert renal and cardiovascular protective effects by improving endothelial function and microcirculation, suppressing inflammation and oxidative stress, maintaining mitochondrial homeostasis, and attenuating fibrosis. In recent years, large-scale clinical studies have further extended the benefits of GLP-1RAs beyond glycaemic control and weight reduction to improved kidney outcomes, reduced major cardiovascular events, and benefits in obesity-related heart failure with preserved ejection fraction. Meanwhile, natural products, characterised by multi-component, multi-target, and multi-pathway actions, may provide a complementary strategy for integrated CKM management by simultaneously improving glucose and lipid metabolic disturbances, insulin resistance, inflammation, and oxidative stress, while attenuating cardiac remodelling, kidney injury, and fibrosis. Emerging studies have shown that some natural products can concurrently improve metabolic, cardiac, and renal phenotypes in CKM-related diseases or composite disease models. This review focuses on the interactions among the metabolic, renal, and cardiovascular systems in CKM, summarises the biological basis and signalling mechanisms of the GLP-1/GLP-1R system, and highlights the mechanistic and clinical evidence supporting GLP-1RA-mediated protection against obesity- and T2DM-related metabolic dysfunction and cardiorenal injury. The potential value of natural products in comprehensive CKM intervention and future research directions are also discussed.
SN - 2296-634X
ER -